Below is a screenshot of the Abraxane profile page at AndrewNava.com, a biotechnology and pharmaceutical database for institutional and retail investors, analysts, traders, consultants, executives, and professionals to track relevant industry information. Disclosure: No positions
As of June 2010, the database covers over 290 publicly-traded biotechnology and pharmaceutical companies, 100's of clinical trials from more than 1000 approved and development-stage drugs, devices and diagnostics, and over 800 company milestones across 17 different catalyst types.
The screenshot above highlights two of the recent clinical trials presented at ASCO, including data from the phase 3 Abraxane study in first-line NSCLC and the phase 2 first-line pancreatic cancer study in combination with gemcitabine.
Andrew Nava, LLC provides institutional and retail healthcare investors with buy-side equity research tools which focus on value-driven investing, profitable trading ideas and clinical, commercial, and regulatory catalysts. Our research is supported by consulting with KOL's, industry professionals, company
management, and our database of clinical trial data and upcoming company milestones.
Disclosure: No positions